Abstract 6468: Nodular lymphocyte predominant hodgkin lymphoma: A national cancer database analysis with focus on hispanics

Abstract Background:Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare and distinct subtype of Hodgkin Lymphoma.(PMID 26149294) 80% manifest at early stages, with a male and black race predilection.(PMID 26149195) Previous analysis have shown similar survival of Hispanics (HI) compared to Non-Hispanics (NH).(J Clin Oncol 10.1200/JCO.2023.41.16_suppl.e19512) This National Cancer Database (NCDB) analysis aims to clarify how sociodemographic factors affect presentation and survival in HI vs NH patients with NLPHL. Methods:Data were analyzed on NLPHL patients in the United States reported to the NCDB 2004-2019. Demographic and treatment characteristics were compared between ethnic groups. Kaplan-Meier and Cox regression analyses were used to compare overall survival (OS) between HI and NH populations. Multivariate analysis and propensity score matching was performed. Results:Of 5517 of NLPHL patients, 379 were HI, and 4904 NH. Male gender and white race predominated for both. HI were diagnosed at a younger median age of 44 years (y) vs 48 y for NH, p=0.001. Most patients were diagnosed between years 2016-2019. Stage I predominated for both, p<0.001. As to Charlson-Deyo score ≥2, both HI and NH had 4%. Private insurance as primary payer was the most prevalent type for HI (53%) and NH (65%). HI had a higher percentage of unknown/uninsured, 12% vs 6% for NH, p<0.001. In relation to census median income (2008-2012), the most prevalent bracket for HI (27%) was $48,000-$62,000, and for NH (35%) was >$63,000. Regarding median income of Citation Format: Esteban Toro Velez, Daniel Rosas, Carolina Velez-Mejia, Qianqian Liu, Joel Michalek, Adolfo Enrique Diaz Duque. Nodular lymphocyte predominant hodgkin lymphoma: A national cancer database analysis with focus on hispanics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6468.